After a recent scan, we can see that Diplomat Pharmacy, Inc. (NYSE:DPLO) has a Shareholder Yield of -0.092286 and a Shareholder Yield (Mebane Faber) of -0.50379. The first value is determined by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the outfit is giving back to shareholders via a few other avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.
Accumulating knowledge about the share market can be a big part of the investment planning process. Proper allocation of equity investments is also an vital factor. Finding the proper mix of stocks may end up being more vital than the single stocks further to the portfolio. Determining the correct asset allocation can depend on variables such as uncertainty appetite and financial goals. These goals may be short-term, medium term, or longer-term. Investors will Often times must think through how aggressive they will be when buying stocks. This can also depend on the overall time horizon and uncertainty tolerance. Some investors might be unfazed by continuous market fluctuations. Others may be much more sensitive, and they may must adjust their plans accordingly.
Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 0.107630. Free cash flow (FCF) is the cash produced by the enterprise minus capital expenditure. This cash is what a enterprise uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a useful gadget in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow. The FCF Score of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 0.642575. Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.
The Gross Margin Score is determined by viewing at the Gross Margin and the overall stability of the enterprise over the duration of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 41.00000. The more stable the enterprise, the lower the score. If a enterprise is less stable over the duration of time, they will have a higher score.
Valuation Scores
The Piotroski F-Score is a scoring system between 1-9 that determines a outfit’s financial strength. The score helps think through if a enterprise’s stock is valuable or not. The Piotroski F-Score of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 5. A score of nine shows a high value stock, while a score of one shows a low value stock. The score is determined by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also determined by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also calculated by change in gross margin and change in asset turnover.
The ERP5 Rank is an investment gadget that analysts use to unveil undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 3383. The lower the ERP5 rank, the more undervalued a enterprise is thought to be. The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable enterprise trading at a good price. The formula is determined by viewing at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 5676. A enterprise with a low rank is considered a good enterprise to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.
The Q.i. Value of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 47.00000. The Q.i. Value is a useful gadget in determining if a enterprise is undervalued or not. The Q.i. Value is determined using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the enterprise is thought to be.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Price Index
The Price Index is a ratio that shows the return of a stock price over a past course. The price index of Diplomat Pharmacy, Inc. (NYSE:DPLO) for last month was 0.77351. This is determined by taking the current stock price and dividing by the stock price one month ago. If the ratio is greater than 1, then that means there has been an accelerate in price over the month. If the ratio is less than 1, then we can think through that there has been a decrease in price. Similarly, investors look up the stock price over 12 month periods. The Price Index 12m for Diplomat Pharmacy, Inc. (NYSE:DPLO) is 0.85475. Some of the best financial predictions are formed by using a variation of financial tools. The Price Range 52 Weeks is one of the tools that investors use to think through the lowest and highest price at which a stock has traded in the previous 52 weeks. The Price Range of Diplomat Pharmacy, Inc. (NYSE:DPLO) over the past 52 weeks is 0.544000. The 52-week range can be found in the stock’s quote summary.
Ever wonder how investors predict positive stock price momentum? The Cross SMA 50/200, also known as the “Golden Cross” is the fifty day moving average divided by the two hundred day moving average. The SMA 50/200 for Diplomat Pharmacy, Inc. (NYSE:DPLO) is at present 0.84443. If the Golden Cross is greater than 1, then the 50 day moving average is above the 200 day moving average – indicating a positive stock price momentum. If the Golden Cross is less than 1, then the 50 day moving average is below the 200 day moving average, indicating that the price might drop.
The Value Composite One (VC1) is a method that investors use to think through a enterprise’s value. The VC1 of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 33. A enterprise with a value of 0 is thought to be an undervalued enterprise, while a enterprise with a value of 100 is considered an overvalued enterprise. The VC1 is determined using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is determined with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Diplomat Pharmacy, Inc. (NYSE:DPLO) is 45.
As many veteran investors have already seen, market movements are extremely uncomfortable to accurately predict. Financial news outlets are always producing headlines and offering predictions for future market performance. Sometimes the predictions are right, and occasionally the predictions are wrong. Investors may have a uncomfortable time separating fact from fiction when it comes to bullish and bearish sentiment. Adjusting the portfolio based strictly on headlines can be tempting for the amateur investor. Filtering out the noise and focusing on the pertinent data can aid keep the individual focused and on track. Straying from the plan and basing investment decisions on news headlines may lead to portfolio confusion down the road. Crunching the numbers and paying attention to the vital economic data can greatly aid the investor see through the smoke when markets get muddled.
Diplomat Pharmacy, Inc. (NYSE:DPLO) has a Price to Book ratio of 1.488759. This ratio is determined by dividing the current stock price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some alternate ratios, the enterprise has a Price to Cash Flow ratio of 15.220027, and a current Price to Earnings ratio of 496.809070. The P/E ratio is one of the most common ratios used for figuring out whether a enterprise is overvalued or undervalued.
As we move closer towards the end of the year, investors may be undertaking a portfolio review. Reviewing trades over the past six months, investors should be able to see what has worked and what has not. There might be some stocks that have outperformed the market, and there might be some underperformers as well. Focusing on what has worked so far this year may aid provide a easier picture for future moves. Pinpointing what went wrong can also aid the investor see which areas of the portfolio need improvement. If the share market continues on to reach new heights, investors might be viewing to lock in some profits before making the next big trade.
